Nick Leschly

Nick Leschly is the current Chief Kairos Officer at 2seventy bio. Prior to this, they served as the CEO of bluebird bio from October 2010 to November 2021. During their time at bluebird, the company made significant progress in gene therapy, helping to make hope a reality for patients with severe genetic diseases. Some of their accomplishments include later stage clinical programs in Adrenoleukodystrophy and Thalassemia, as well as an earlier program in Sickle Cell Disease.

Before their time at bluebird, Leschly was a partner at Third Rock Ventures from February 2007 to September 2010. Nick also worked at Millennium Pharmaceuticals from January 2001 to June 2006 as the Velcade Project Lead. Nick's career began at MedXtend, where they served as the CEO from December 1999 to March 2001.

Nick Leschly has dedicated their career to helping those with severe genetic disorders. Nick's passion and dedication have helped countless patients receive the treatment they need and have given hope to many more.

Nick Leschly completed their undergraduate degree in Molecular Biology at Princeton University and then went on to earn their MBA from The Wharton School.

Philip Gregory - Chief Scientific Officer, Chip Baird - Chief Financial Officer, and Susan Abu - Absi - Chief Technology & Manufacturing Officer report to Nick Leschly.